深度雷达挖掘揭示了超宽的冠状病毒中和抗体,针对多个尖端表观
Jonathan Hurtado1, Thomas F Rogers2, David B Jaffe3
1Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA.
Cell reports
|June 7, 2024
概括
研究人员确定了强大的中和抗体,TXG-0078和CC24.2,对各种冠状病毒和SARS-CoV-2变体有效. 这些抗体显示出开发广谱疗法和泛冠状病毒疫苗的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 开发针对冠状病毒的广泛有效的疫苗和治疗方法是关键的全球卫生优先事项.
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 流行病突显了需要广泛的冠状病毒对策的需要.
- 了解针对SARS-CoV-2的抗体库对于设计有效干预措施至关重要.
研究的目的:
- 隔离和表征具有广泛中和活性的SARS-CoV-2特定单克隆抗体 (mAbs).
- 为了确定全新冠状病毒治疗和疫苗开发的新型抗体标和表征物.
- 评估针对当前和新出现的SARS-CoV-2变体的联合抗体疗法的潜力.
主要方法:
- 从COVID-19幸存者和接种疫苗的人群中选B细胞库,以分离SARS-CoV-2特定的mAbs.
- 抗体结合宽度对抗不同类型的α和β冠状病毒的表征.
- 对各种SARS-CoV-2变种进行皮层映射和中和测定,包括Omicron亚系.
- 在相关动物模型中对抗体尾酒的体内疗效研究.
主要成果:
- 隔离了超过9000个针对SARS-CoV-2的mAbs,为抗体库提供了广泛的视图.
- TXG-0078是一种特定于N终端域 (NTD) 的mAb,对α和β冠状病毒进行了广泛的中和.
- CC24.2,一种特定于受体结合域 (RBD) 的mAb,表现出强大的泛沙尔贝病毒中和,包括针对BQ.1.1和XBB.1.5.5等变体.
- TXG-0078和CC24.2的组合在体内给予了保护.
结论:
- TXG-0078和CC24.2是治疗抗体尾酒的有希望的候选者.
- 这些抗体可以作为设计下一代泛冠状病毒疫苗的宝贵模板.
- 鉴定到的抗体扩大了对抗当前和未来的冠状病毒威胁的工具包.
相关概念视频
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:25Rapid Identification of Pathogens
MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...